medigraphic.com
ISSN 1608-8921 (Print)

2023, Number 2

<< Back Next >>

Gaceta Médica Espirituana 2023; 25 (2)

HeberFERON in the treatment of patients with basal cell carcinoma of the ear

Sánchez LV, Brito GE, Martínez FB, Álvarez GY, Bello RI

Language: Spanish
References: 16
Page: 1-12
PDF size: 198.5 Kb.


ABSTRACT

Background: Basal cell carcinoma of the auricular region is one of the most aggressive cancers and with the worst prognosis, is usually destructive and mutilating, therefore conservative treatment, such as the use of interferons, is important in routine medical practice.
Objective: To evaluate the results of HeberFERON application in a series of patients with basal cell carcinoma in the auricular region.
Methodology: An observational, descriptive and longitudinal study was conducted on a series of cases with clinical, dermoscopic and histopathologic diagnosis of basal cell carcinoma of the ear treated with HeberFERON at the Center Polyclinic in Sancti Spíritus city, during the period from February 20, 2017 through December 20, 2022. A total of 29 patients were included in the study. An evaluation was conducted at the start of treatment, during treatment, and 16 weeks after treatment; the patients were treated with 10.5 IU of HeberFERON by perilesional and intradermal injections three times a week until completing nine doses. The variables were the response to the treatment and the presence or absence of any adverse events.
Results: The male sex predominated, location in the ear turbinate, clinical subtype ulcerative nodule and solid histologic subtype, with a complete response in the majority of patients. The most common adverse events were injection site pain, fever, edema, and perilesional erythema.
Conclusions: The response to treatment was favorable in most patients, and the adverse events observed were those described in the literature, with no change in pharmacologic attitude.


REFERENCES

  1. Alcalá Pérez D, Medina Bojórquez A, Torres González S, Navarrete Franco G, Ramos Garibay A, Peralta PedreroML, et al. Correlación clínica, histológica y dermatoscópica de carcinoma basocelular. Rev Cent Dermatol Pascua[Internet] 2013 [citado 19 Dic 2022];22(1):5-14. Disponible en: https://www.medigraphic.com/pdfs/derma/cd-2013/cd131a.pd

  2. Gallegos Hernández JF, Martínez Méndez MA, Ábrego Vázquez JA, Hernández Sanjuan M, Minauro Muñoz GG,Ortiz-Maldonado AL. Características clínicas de los tumores malignos originados en el pabellón auricular. Cirugía yCirujanos [Internet]. 2015 [citado 19 Dic 2022];83(6):473-77. Disponible en: https://www.elsevier.es/es-revista-cirugiacirujanos-139-pdf-S0009741115001309

  3. La Torre J, Botache R, Chidichimo A. Colgajo en filete como tratamiento de carcinoma basocelular recidivado.Revista Argentina de Cirugía Plástica [Internet]. 2016 [citado 19 Dic 2022];22(3):101-104. Disponible en:http://adm.meducatium.com.ar/contenido/articulos/6901010104_492/pdf/6901010104.pdf

  4. Sánchez Linares V, Martínez Fando B, Hernández González T, González Pérez A, Bello Rivero I. Tratamiento decarcinoma basocelular en la nariz con una combinación de interferones Alpha-2b y Gamma. Rev haban cienc méd[Internet]. 2022 [citado 6 Ene 2023];21(5). Disponible en:https://revhabanera.sld.cu/index.php/rhab/article/view/4723/3218

  5. Anasagasti Angulo L, García Vega Y, Collazo Caballero S, Jiménez Barban Y, Tijerino Arrieta E. HeberFERON,formulation based on IFNs alpha 2b and gamma for the treatment of non-melanoma skin cancer. AMJ [Internet]. 2017[citado 6 Ene 2023];10(6):509-15. Disponible en: https://amj.net.au/index.php/AMJ/article/view/3013

  6. Sánchez Linares V, Cifuentes Suárez JP, Martínez Cuervo JJ, Román Simón M, Pérez García C, Bello Rivero I.Carcinoma basocelular del rostro tratados con HeberFERON. Gac Méd Espirit [Internet]. 2019 [citado 19 Dic2022];21(2):87-97. Disponible en: http://scielo.sld.cu/pdf/gme/v21n2/1608-8921-gme-21-02-87.pdf

  7. Quiñones Venegas R, Valenzuela Barba X, González Ramírez RA. Cáncer de piel no melanoma de la hélice: ¡eldermatoscopio está de nuestro lado!. Dermatol Rev Mex [Internet]. 2015 [citado 19 Dic 2022];59:175-180. Disponibleen: https://silo.tips/download/cancer-de-piel-no-melanoma-de-la-helice-el-dermatoscopio-esta-de-nuestro-lado-de

  8. Gutiérrez Gómez C, Avila Romay A, Zepeda Alcántara C, Cárdenas Mejía A. Experiencia en reconstrucción auricularen cáncer de piel con colgajo en «quesadilla». Cir plást iberolatinoam [Internet]. 2008 [citado 19 Dic 2022];34(2):101-6. Disponible en: https://scielo.isciii.es/pdf/cpil/v34n2/articulo_101.pdf

  9. Morales Gordillo V, Padial Gómez -Torrente A, Armario Hita JC, Fernández Vozmediano JM. Cirugía básica delpabellón auricular. Piel [Internet]. 2008 [citado 19 Dic 2022];23(6):315-20. Disponible en:https://www.sciencedirect.com/sdfe/pdf/download/eid/1-s2.0-S0213925108710426/first-page-pdf

  10. Camacho Salas CA, Barrera Gamboa JC, Vaca Grisales D. Colgajo condrocutáneo de Antia-Buch para coberturade defectos extensos del pabellón auricular. Cir. plást. Iberolatinoam [Internet]. 2020 [citado 19 Dic 2022];46(4):449-54. Disponible en: https://scielo.isciii.es/pdf/cpil/v46n4/1989-2055-cpil-46-04-0449.pdf

  11. Jury SJ, Jury SC, Sepúlveda ST, Jury SO. Colgajo giratorio retroauricular. Rev. Otorrinolaringol. Cir. Cabeza Cuello[Internet]. 2020 [citado 6 Ene 2023];80(3):295-6. Disponible en: https://www.scielo.cl/pdf/orl/v80n3/0718-4816-orl-80-03-0295.pdf

  12. Ferrá Torres TM, Sánchez Rodríguez ES, Ballester Caballero Y, Sallary Gutiérrez K. Caracterización de pacientescon carcinoma basocelular tratados con HeberFERON. AMC [Internet]. 2020 [citado 6 Ene 2023];24(2):240-50.Disponible en: http://scielo.sld.cu/pdf/amc/v24n2/1025-0255-amc-24-02-e7136.pdf

  13. Piña Rodríguez Y, Monzón Díaz Y, Piña Russinyol JJ, Alapón Guillarte A. HeberFERON, experiencia en la provinciade Matanzas. Folia Dermatológica Cubana [Internet]. 2019 [citado 19 Dic 2022];13(1). Disponible en:https://revfdc.sld.cu/index.php/fdc/article/view/146/168

  14. López Pupo N, Manganelly Fonseca Y, Tablada Robinet ME, Jacas Portuondo AL, Girón Maturell Y. Utilidad delHeberFERON® en pacientes con carcinoma basocelular. Medisan [Internet]. 2021 [citado 6 Ene 2023];25(6).Disponible en: https://medisan.sld.cu/index.php/san/article/view/3867/html

  15. Rojas Rondón I, Vigo Aranguren L, García Vega Y, Bello Rivero I, Duncan Roberts Y. Seguridad del HeberFERONen pacientes con carcinoma basal palpebral. Rev cuba oftalmol [Internet]. 2021 [citado 6 Ene 2023];34(1):e1131.Disponible en: http://scielo.sld.cu/pdf/oft/v34n1/1561-3070-oft-34-01-e1131.pdf

  16. Drake Sosa DV, Rojas Barlys L. HeberFERON en pacientes con carcinoma basocelular tratados en el municipioPuerto Padre, Las Tunas. Rev Electrón Dr. Zoilo E. Marinello Vidaurreta [Internet]. 2018 [citado 19 Dic 2022];43(6).Disponible en: https://revzoilomarinello.sld.cu/index.php/zmv/article/view/1573/pdf_531




2020     |     www.medigraphic.com